Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers
Authors:
- 13 October 2005
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 96 (7) , 964-969
Abstract
Patients with metastatic bone disease often have severe bone pain and debilitating skeletal complications. Zoledronic acid is the only bisphosphonate shown to be safe and effective in reducing skeletal‐related events (SREs), including pathological fractures, spinal cord compression, and radiation or surgery to bone in patients with bone metastases from advanced prostate cancer or renal cell carcinoma (RCC). In both tumour types, zoledronic acid significantly decreased the overall risk of developing an SRE, delayed their onset and significantly reduced the incidence of SREs compared with placebo. In patients with RCC, zoledronic acid also significantly delayed the time to progression of bone lesions by 5 months compared with placebo. Zoledronic acid is safe and well tolerated with long‐term use.Keywords
This publication has 16 references indexed in Scilit:
- Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumorsCancer, 2004
- Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate CancerJNCI: Journal of the National Cancer Institute, 2004
- 615 Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastasesEuropean Urology Supplements, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Role of Bisphosphonates in Prostate CancerEuropean Urology, 2004
- Metastatic renal cell carcinomaCurrent Treatment Options in Oncology, 2003
- Zoledronic acid delays the onset of skeletal‐related events and progression of skeletal disease in patients with advanced renal cell carcinomaCancer, 2003
- Renal cell carcinoma: current status and future directionsCritical Reviews in Oncology/Hematology, 2003
- Hematologic malignancies: New developments and future treatmentsSeminars in Oncology, 2002
- Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic AcidThe Journal of Pharmacology and Experimental Therapeutics, 2002